Vaccination within  weeks of the first dose of avelumab and while on study is prohibited except for administration of inactivated vaccines (e.g. inactivated influenza vaccines).
Vaccination within  weeks of the first dose of avelumab and while on study.
Vaccination within  weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
Vaccination within  days of the first dose of study drugs and while on trial is prohibited, except for administration of inactivated vaccines (for example, inactivated influenza vaccine).
Vaccine administration within  weeks of M administration. Vaccination with live vaccines while on trial is prohibited. Administration of inactivated vaccines is allowed (for example, inactivated influenza vaccines).
Vaccination within  weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines
Vaccine administration within  weeks of M administration. Vaccination with live vaccines while on trial is prohibited. Administration of inactivated vaccines is allowed (for example, inactivated influenza vaccines).
Vaccination within  weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
Vaccination within  weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines
Vaccination within  weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination (live attenuated virus) within  weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.
Live virus vaccination within  weeks of the first dose of avelumab (inactivated vaccines are allowed)
Vaccination within  weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Any vaccination within  weeks of the first dose of avelumab, with the following exceptions:\r\n* Administration of inactivated vaccines, including inactivated flu vaccines, are allowable; however, they should not be given within  weeks prior to starting study treatment
Vaccination within  weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines
Vaccination within  weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination within  days of the first dose of avelumab and while on trial is prohibited, except for administration of inactivated vaccines (for example, inactivated influenza vaccine)
Vaccination within  weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination with live inactivated viral strains for the prevention of infectious diseases within  weeks of the start of the study treatment, inactivated influenza vaccines are permitted while on trial
Vaccination within  weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines)
Vaccination within  weeks of the st dose of pembrolizumab and while on study is prohibited EXCEPT for administration of inactivated vaccines (e.g. inactivated influenza vaccine)
Vaccination within  weeks of the first dose of study treatment is prohibited except for administration of inactivated vaccines;
Vaccination with live or live/attenuated viruses within  days of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination within  weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination within  weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines).
Vaccination within  weeks prior to the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Vaccination within  weeks of study enrollment and while on trial is prohibited except for administration of inactivated vaccines.
Vaccination within  weeks of first dose of AGEN and while on study except for administration of inactivated vaccines (e.g., inactivated influenza vaccines).
Vaccination within  weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccines
Patient who has received vaccination within  weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines